What is the 13F Pro Quality Score for CYTK?

13F Pro ranks CYTOKINETICS INC (CYTK) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View CYTK's current score at https://13fpro.ai/research/CYTK (free sign-up required for the full ranking).

Which hedge funds own the most CYTK stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of CYTK include BlackRock,, FMR, WELLINGTON MANAGEMENT GROUP LLP. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/research/CYTK as soon as new 13F filings post.

Where does 13F Pro source CYTK data?

All CYTOKINETICS INC fundamentals and ownership data come directly from SEC EDGAR. CYTOKINETICS INC files with the SEC under CIK 1061983. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is CYTK in?

CYTOKINETICS INC (CYTK) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is CYTK research updated on 13F Pro?

CYTK's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

CYTOKINETICS INC(CYTK)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1061983 CYTK stock profile & AI dashboard →

13F Pro Quality Score

28.0/100

Rank #2,453 of 2,879 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

98.6/100

Profitability

2.6/100

Balance Sheet

2.6/100

Earnings Quality

30.0/100

Free Cash Flow

2.9/100

Institutional Flow

56.6/100

Revenue Scale

16.3/100

Dilution Risk

2.6/100

CYTK Stock Analysis & AI Quality Score

AI stock analysis and institutional research for CYTOKINETICS INC (CYTK), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores CYTK at 28.0/100 on a 32-signal composite quality model, placing it at rank #2,453 of 2,879 stocks — the bottom half of the AI-ranked universe. CYTK scores in the top quartile across revenue growth (98.6). Areas of concern include profitability (2.6) and balance sheet strength (2.6), which score below median versus the broader universe. Shareholder dilution risk is elevated at 2.6/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), CYTOKINETICS INC reports quarterly revenue of $19.4M, net income of $-206.0M, free cash flow of $-151.4M. Top institutional holders of CYTK by reported 13-F value include BlackRock,, FMR, WELLINGTON MANAGEMENT GROUP LLP, based on the most recent SEC filings. CYTK trades on the Nasdaq exchange and files with the SEC under CIK 1061983. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate CYTK daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for CYTOKINETICS INC directly from SEC EDGAR. CYTOKINETICS INC's 13F Pro composite quality score has ranged between 7 and 51 since 2021, currently 28.0 — a stable long-term trajectory across 56 quarterly and live scoring snapshots.

✦

Fun facts about CYTOKINETICS INC

Quirks, history, and lore behind CYTK — the kind of stuff that makes a stock memorable.

1
The Basics
A small-cap biopharmaceutical company headquartered in South San Francisco · focused entirely on muscle biology · listed on Nasdaq.
2
The Numbers
Largely pre-revenue for most of its life, burning cash on R&D · but a late-stage drug candidate drew major partnership deals worth hundreds of millions in potential milestones.
3
The History
Founded around 2001, it spent two decades quietly studying how sarcomere proteins control muscle contraction — a niche so narrow most investors couldn't spell it.
4
The Secret
Its lead program targets cardiac muscle, not skeletal muscle — specifically aiming to help the heart pump harder in patients with heart failure with reduced ejection fraction.
5
The Lore
Its partnership with AstraZeneca on its cardiac myosin activator program put a Big Pharma stamp of approval on a science platform most had slept on for years.
6
The Giveaway
The company's drug omecamtiv mecarbil — and its next-gen cardiac program aficamten for hypertrophic cardiomyopathy — are the reason the word 'cytokinetics' is finally on Wall Street's radar.

▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q1 2026

$19.4M

Net Income

Q1 2026

$-206.0M

Free Cash Flow

Q1 2026

$-151.4M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

+376.6% YoY

$88.0MFY 2025

FY20 $55.8MFY22 $94.6MFY24 $18.5MFY25 $88.0M

Net Income

-33.2% YoY

$-785.0MFY 2025

FY20 $-127.3MFY22 $-389.0MFY24 $-589.5MFY25 $-785.0M

Operating Income

-14.2% YoY

$-612.3MFY 2025

FY20 $-93.9MFY22 $-324.2MFY24 $-536.2MFY25 $-612.3M

EPS (Diluted)

-24.3% YoY

$-6.54FY 2025

FY20 $-1.97FY22 $-4.33FY24 $-5.26FY25 $-6.54

Total Assets

+1.6% YoY

$1.42BFY 2025

FY20 $533.8MFY22 $1.01BFY24 $1.40BFY25 $1.42B

Total Debt

-54.4% YoY

$287.6MFY 2025

FY20 $46.2MFY22 $650.5MFY24 $631.0MFY25 $287.6M

Op. Cash Flow

-28.8% YoY

$-510.0MFY 2025

FY20 $8.9MFY22 $-299.5MFY24 $-395.9MFY25 $-510.0M

Metric	FY 2025	FY 2024	FY 2022	FY 2020	FY 2019	FY 2018
Revenue	$88.0M +376.6%	$18.5M -80.5%	$94.6M +69.4%	$55.8M +107.8%	$26.9M -14.7%	$31.5M
Net Income	$-785.0M -33.2%	$-589.5M -51.6%	$-389.0M -205.6%	$-127.3M -4.6%	$-121.7M -14.5%	$-106.3M
Operating Income	$-612.3M -14.2%	$-536.2M -65.4%	$-324.2M -245.1%	$-93.9M +5.0%	$-98.9M -11.2%	$-88.9M
EPS (Diluted)	$-6.54 -24.3%	$-5.26 -21.5%	$-4.33 -119.8%	$-1.97	—	—
Total Assets	$1.42B +1.6%	$1.40B +38.1%	$1.01B +90.1%	$533.8M +84.2%	$289.8M +37.2%	$211.2M
Total Debt	$287.6M -54.4%	$631.0M -3.0%	$650.5M +1307.8%	$46.2M +2.6%	$45.1M +0.1%	$45.0M
Operating Cash Flow	$-510.0M -28.8%	$-395.9M -32.2%	$-299.5M -3449.2%	$8.9M +109.8%	$-90.9M +10.2%	$-101.2M

AI Insight: CYTK Ratio Trends

Cytokinetics shows persistently negative returns with ROA deteriorating from -37.6% in Q2 2024 to -64.7% in Q1 2026.

• ROA declined from -37.6% in Q2 2024 to -64.7% in Q1 2026, indicating worsening asset utilization.

• Operating margin of -167.0% in Q2 2025 reflects substantial operating losses relative to revenue.

• ROIC was -69.5% in Q2 2024 and -91.2% in Q3 2024, showing negative returns on invested capital.

⚠ Sparse data across key profitability metrics limits visibility into operational trends and financial health.

⚠ Debt-to-equity ratio of 5.90 in Q2 2024 indicates high leverage amid persistent losses.

Get alerted when CYTK's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for CYTOKINETICS INC including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of CYTK

BlackRock, Inc.
$1.1B16,548,011 sh
FMR LLC
$706.8M10,723,140 sh
WELLINGTON MANAGEMENT GROUP LLP
$527.9M8,009,489 sh
VANGUARD PORTFOLIO MANAGEMENT LLC
$385.2M5,843,782 sh
STATE STREET CORP
$378.7M5,745,193 sh
VANGUARD CAPITAL MANAGEMENT LLC
$361.8M5,488,634 sh
Avoro Capital Advisors LLC
$219.7M3,333,333 sh
GEODE CAPITAL MANAGEMENT, LLC
$212.0M3,215,415 sh
BANK OF AMERICA CORP /DE/
$206.0M3,125,436 sh
RTW INVESTMENTS, LP
$179.4M2,721,158 sh

Fund	Value	Shares
BlackRock, Inc.	$1.1B	16,548,011
FMR LLC	$706.8M	10,723,140
WELLINGTON MANAGEMENT GROUP LLP	$527.9M	8,009,489
VANGUARD PORTFOLIO MANAGEMENT LLC	$385.2M	5,843,782
STATE STREET CORP	$378.7M	5,745,193
VANGUARD CAPITAL MANAGEMENT LLC	$361.8M	5,488,634
Avoro Capital Advisors LLC	$219.7M	3,333,333
GEODE CAPITAL MANAGEMENT, LLC	$212.0M	3,215,415
BANK OF AMERICA CORP /DE/	$206.0M	3,125,436
RTW INVESTMENTS, LP	$179.4M	2,721,158

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put CYTK on your watchlist

Track score changes the day CYTOKINETICS INC files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is CYTK a good stock to buy?

13F Pro's AI-powered analysis of CYTOKINETICS INC (CYTK) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for CYTK are available on the CYTK stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own CYTK?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling CYTK. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of CYTOKINETICS INC's investment landscape.